17 April

International Severe Asthma Forum



International Sever Asthma Forum – ISAF Digital 2021 Digital Scientific Programme Saturday, April 17, 2021

(All times are in CET)

08:45 – 09:00	Opening remarks Marek Jutel, Poland Matteo Bonini, Italy Ioana Agache, Romania
9:00 - 10:00	Session 1: The basics of severe asthma
	Chairs: Marek Jutel, Poland Matteo Bonini, Italy
09:00 - 09:15	Mechanisms - Cezmi Akdis, Switzerland
09:15 - 09:20	Q&A
09:20 - 09:35	Phenotypes and Endotypes – Kian Fan Chung, UK
09:35 – 09:40	Q&A
09:40 – 09:55	Biomarkers - Kenji Izuhara, Japan
09:55 – 10:00	Q&A
10:00 – 10: 30	Poster viewing and Networking Break
10:30 - 11:30	Session 2: Guidelines and Perspectives
	Chairs: Stefano del Giacco, Italy Ibon Eguiluz-Gracia, Spain
10:30 - 10:45	GINA Guidelines Update - Antonio Spanevello, Italy
10:45 - 10:50	Q&A
10:50 - 11:05	EAACI Biologicals Guidelines – Recommendations for Severe Asthma
	Ioana Agache, Romania
11:05 – 11:10	Q&A
11:10 – 11:25	Imaging in severe asthma– Nair Parameswaran, Canada
11:25 – 11:30	Q&A
11:30 – 11:45	Poster viewing and Networking Break
11:45 – 12:10	Session 3: Pro&Con Sessions - Electronic Health in Severe Asthma
	Chairs: Tomas Chivato, Spain Cristiano Caruso, Italy
11:45 – 11:55	PRO: David Drummond, France
11:55 – 12:05	CON: Joao Fonseca, Portugal
12:05 – 12:10	Q&A
12:10 – 12:20	Poster viewing and Networking Break
12:00 – 13:15	Industry Session (parallel track - further information on the website)
12:20 – 12:45	Session 4: Pro&Con Sessions - Immunotherapy in Severe Asthma (AIT) Chairs: Ferda Oner Erkekol, Turkey Antonio Spanevello, Italy
12:20 - 12:30	PRO: Marek Jutel, Poland
12:30 - 12:40	CON: Walter Canonica, Italy
12:40 – 12:45	Q&A



17 April

International Severe Asthma Forum



12:45 – 13:30 Lunch Poster Sessions and Networking Break

Group 1: Allergic Airway Disease *Chairs: Cristiano Caruso, Italy*

P24 – Prevalance and serodominance of dermatophagodies pteronyssinus mites in pediatrci population with moderate-severe persisent astham phenotype

Paloma Poza-Guedes, Spain

P79 - Diagnosis Of Allergic Diseases By The Skin Prick Test With Allergens From Peking Union Medical College Hospital: A Meta-Analysis

Juan Liu, China

P63 - Changes In Heart Rate Variability Indicators In Children With Asthma, Depending On The Severity Of The Allergic History

Pavel Berezhanskiy, Russia

P62 - Efficacy And Safety Of Subcutaneous Immunotherapy For Allergic Rhinitis And Allergic Asthma In China *Juan Liu, China*

P58 - Dyspnea In Young Man Suffering From Pollen Allergy – Not Always Asthma *Marika Gawinowska, Poland*

P55 - Recent trend in the prevelence of predominant aeroallergens among the populatioon of the year 2019 with refrence to house dust mites (hdm) and insects Lakshmi Keshava, India

P49 - Predicting The Effectiveness Of ASIT To Grass Allergens Anatoliy Bala, Russia

P47 - Sensitization To CCD And ASIT To Birch In The Russian Population Anatoliy Bala, Russia

P42 - Seafood Allergy Trends In The Asthmatic Population In The Dominican Republic: How Much Immune-Related Comorbidities Contribute To Increased Severity?

Leandro Tapia, Spain

P41 - Increased Environmental Allergy Severity Among Asthmatic Populations In Dominican Republic Leandro Tapia, Spain

P40 - Association Of ABPA In Children With Poor Control Of Asthma Manvi Singh, India

Group 2: Biomarkers

Chairs: Maia Rukhadze, Georgia | Edward Knol, The Netherlands

P82 - Systemic Production Of Nitric Oxide And IL-17A During Severe Allergic Asthma: Immunomodulation By The Helminth Echinococcus Granulosus

Sara Benazzouz, Algeria

P22 - Combination Of Transcriptomics And Genomics For The Identification Of Novel Loci Of Response To Asthma Treatment With Glucocorticosteroids

Natalia Hernandez-Pacheco, Spain

P16 - Differential Gene Expression Analysis Of Airway Remodeling Signaling Pathways In Severe Bronchial Asthma *Alena Minina, Belarus*



17 April

International Severe Asthma Forum



P31 - Metabolomic Signatures Associated To Allergic Asthma Control With Differential Pharmacological Interventions. Applicability For New Biomarker Strategies

Maria Isabel Delgado-Dolset, Spain

P34 - Measurement Of EDN, MPO And NGAL In Nasal Mucosal Lining Fluid Vs. Blood *Eleftheria Pertsinidou, Sweden*

P37 - Characteristics Of The Genomics And Metagenomics Of Asthma Severity (GEMAS) Study *Javier Perez-Garcia, Spain*

P75 – Allergic and nonallergic asthma biomarkers prioritized by systems biology: sensitivity and specificity analysis *Lucia Cremades-Jimeno, Spain*

P74 - CHI3L1 AND PI3: two time-stable asthma biomarkes able to discriminate asthma severity Maria López-Ramos, Spain

P68 - Serum MicroRNAs As Tool To Predict Early Response To Benralizumab In Severe Eosinophilic Asthma *Jose Rodrigo-Muñoz, Spain*

P66 - Serum MicroRNAs As A Tool To Catalogue Asthmatic Patients In Different Phenotypes/Endotypes Serving As Diagnostic And Prognostic Biomarkers Of The Disease

Marta Gil Martínez, Spain

P65 - Predictors Of Response To Treatments For Difficult/Severe Asthma In Adult Patients: A Scoping Review Carlos Andrés Celis-Preciado, Colombia

P64 - Immunological Markers Of Glucocorticosteroids Insensitivity In Patients With Severe Asthma Carlos Cardoso, Switzerland

P60 - Immunological Markers Of Secondary Immune Insufficiency In Patients With Severe Bronchial Asthma *Ella Churyukina, Russia*

P54 - Transcriptome-Based Identification And Validation Of CRTH2 MRNA Levels In Peripheral Blood Of Adult Patients With Asthma

Asunción García-Sánchez, Spain

P53 - Phenotypic Characteristics Of ILC2s And T- Lymphocytes In Donors And Patients With T2-Driven Bronchial Asthma

Alina Makeeva, Russia

P52 - Investigating The Effects Of Interleukin 33 On Rhinovirus A Induced Gene Expression Changes In Asthmatic Bronchial Epithelial Cells

Rebecca Cooper, UK

Group 3: Clinical management of asthma

Chairs: Ferda Oner Erkekol, Turkey | Joao Fonseca, Portugal

P83 - Severe Eosinophilic Asthma: Phenotypic Structure, Clinical And Functional Features Darima Tsyndymeeva, Russia

P78 – Can near fatal asthma resolve sever uncontrolled T2-astthma? *Lucia Maria Porro, Italy*

P76 - Altitude Climate Treatment (ACT) As An Alternative To Chronic Expensive Third Line Treatments In Severe Asthma: A Case Report

Marieke Drijver-Messelink, Switzerland

P72 - Roadmap To Improve Regional Care For Severe Asthma Patients In The Netherlands *Gert-Jan Braunstahl, The Netherlands*

17 April

International Severe Asthma Forum



P69 - Severe Asthma Patients In Austria And Germany Eckard Hamelmann, Germany

P12 – Phenotype of severe bronchial asthma with fixes airflow obstruction Angelina Kraposhina, Russia

P20 - Could Asthma Severity Level Impact The Perceived Importance Of Patient's Treatment Goals? Results From A Romanian Asthma Survey

Carmen Panaitescu, Romania

P21 - Multidimensional Severe Asthma Burden. Results From A Romanian Patient's Survey *Carmen Panaitescu, Romania*

P32 - Correlations Between Airway Inflammation, Asthma Control And Pulmonary Function In Partly Controlled / Uncontrolled Asthmatic Indian Children

Rashmi Yadav, India

P61 - Loss Of Smell As A Reliable Clinical Biomarker For Severe Asthma And CRS With Nasal Polyps That Predict Sinus Occupancy

José Antonio Castillo, Spain

P57 - Challenges Of Silent Severe Asthma And NERD In Children Gintare Liakaite, Lithuania

P56 - IgG4 Related Disease And Probable Severe Asthma Dina Rnjak, Croatia

P50 - Difficulty In Diagnosing Paucigranulocytic Asthma In A Severe Steroid-Dependent Asthmatic Ronina Covar, USA

Group 4: COVID-19 & psychological aspects of asthma

Chairs: Cristina Boccabella, Italy

P86 - COVID-19 And Asthma In Children: Is There A Link?

Valery Mukhortykh, Russia

P84 - Fatigue, General Psychological Distress And Specific Psychological Symptoms In A Severe Asthma Population Before And After Altitude Climate Treatment (ACT)

Karin Fieten, Switzerland

P80 - Real-Life Impact Of COVID-19 Pandemic Lockdown On The Management Of Pediatric And Adult Asthma: A Survey By The EAACI Asthma Section

Ibon Eguiluz-Gracia, Spain

P77 - Effect Of The SARS-CoV-2 Pandemic On Treatment Processes Of Patients With Severe Asthma Who Were Receiving Monoclonal Antibody Treatment

Gokhan Aytekin, Turkey

P25 – The impact of COVID-19 in patiens with sever asthma under biologic therapies Ana Mesquita, Portugal

P36 - Presenting Prevalence, Characteristics And Outcome Of Asthmatic Patients With T2 Diseases In Hospitalized Subjects With COVID-19 In Madrid, Spain

Marcela Valverde-Monge, Spain

P30 - Health-Psychological Aspects In Persons With Severe Asthma *Lina Rönnebjerg, Sweden*

P35 - Asthma Vs COPD And OSA In COVID19 Patients: Interesting Differences Among Groups Marcela Valverde-Monge, Spain

17 April

International Severe Asthma Forum



P18 - Viral Respiratory Infection And The Link To Wheezing Olena Mozyrska, Ukraine

P13 – Adherence to therapy and quality of life at severe bronchial asthma *Angelina Kraposhina, Russia*

P29 - Relationship Of Health-Related Quality Of Life With Asthma Control And Airway Inflammation In Uncontrolled Asthmatic Indian Children

Rashmi Yadav, India

P43 - COVID-19 In Patients With Severe Asthma Treated With Biologics: Our Experience *Irina Bobolea, Spain*

Group 5: Real life use of biologicals

Chairs: Sejal Saglani, UK |

P87 - Efficacy of Dupilumab in Patients With GINA-Defined Difficult-to-Treat Type 2 Asthma: LIBERTY ASTHMA QUEST Study

Jorge Maspero, Argentina

P85 - Biological Therapy Of Child Bronchial Asthma In Clinical Practice: What To Prefer And How To Choose? *Valery Mukhortykh, Russia*

P81 - Lock In The Bud - The Resolving Effect Of Dupilumab In A Case Of Severe Refractory Asthma Carmelo Sofia, Italy

P73 - One Patient, But Different Biologic Agents Betul Dumanoglu, Turkey

P71 - Indirect Treatment Comparison Of Biologics In Severe Eosinophilic Asthma In Real Clinical Practice *Miramgul Dyneva, Russia*

P70 – Profile of patients with biological threapies in the severe asthma unit of Merida Hospital, Spain *Alicia Mena, Spain*

P11 - Real World Prompt Efficacy Of Mepolizumab In Severe Eosinophilic Asthma And Comorbid Chronic Rhinosinusitis With Nasal Polyps

Ruperto González Pérez, Spain

P17 – Mepolizumab as a steroid-sparing treatment option in a patient with eosinophilic granulomatosis with polyangiitis

Ana Presa, Portugal

P15 - Impact On The Quality Of Life Of Asthmatic Patients Treated With Benralizumab According To Mini-AQLQ Quality Of Life Test

Yaiza Bonilla Pacheco, Spain

P39 - Successful Therapy With Mepolizumab In Patient With Severe Eosinophilic Cough-Predominant Asthma *Joanna Hermanowicz-Salamon, Poland*

P46 - Use Of Two Monoclonal Antibodies For Severe Asthma In Children: A Case Report Nidia Castillón Benavides, Mexico

P45 - Monitoring Disease Progression In Severe Non-Allergic Asthma Patients On Dupilumab Treatment - A Case Series *Inês Farinha, Portugal*

17 April

International Severe Asthma Forum



13:30 – 14:30	Session 5: Severe Asthma in special populations Chairs: Mariana Couto, Portugal Francesco Blasi, Italy
13:30 – 13:45	Severe asthma in women - Apostolos Bossios, Sweden
13:45 – 13:50	Q&A
13:50 – 14:05	Severe asthma in children -Sejal Saglani, UK
14:05 – 14:10	Q&A
14:10 – 14:25	Severe asthma in athletes - Maia Rukhadze, Georgia
14:25 – 14:30	Q&A
11125 11100	
13:30 – 14:45	Industry Session (parallel track - further information on the website)
14:30 – 14:45	Poster viewing and Networking Break
14:45 – 15:45	Session 6: Comorbidities in Severe Asthma
	Chairs: Sebastian Johnston, UK Apostolos Bossios, Sweden
14:45 - 15:00	Bronchiectasis - Francesco Blasi, Italy
15:00 - 15:05	Q&A
15:05 - 15:20	Chronic rhinosinusitis with nasal polyps - Enrico Heffler, Italy
15:20 - 15:25	Q&A
15:25 - 15:40	Alfa-1 antitripsin deficiency - Marc Miravitlles, Spain
15:40 – 15:45	Q&A
15:00 – 16:15	Sister Society Symposium - EAACI - PTA Joint Symposium (parallel track)
15:00 -15:20	Focus on Patient. Personalised therapy for severe asthma - Piotr Kuna, Poland
15:20 -15:25	Q&A
15:25 – 15:45	Diagnosis and allocation to biologics in severe asthma – guidelines of the Polish Society of Allergology - Maciej Kupczyk, Poland
15:45 -15:50	Q&A
15:50–16:10	Biological severe asthma treatment in Poland - pros and cons of drug programme -
16:10 16:15	Aleksandra Kucharczyk, Poland
16:10 –16:15	Q&A
15:45- 16:15	Poster viewing and Networking Break
16:15 – 16:55	Session 7: Severe Asthma and COVID-19 Chairs: Walter Canonica, Italy Edward Knol, The Netherlands Key-note Lecture: Sebastian Johnston, UK
16:50 – 16:55	Q&A
16:55 – 17:10	Closing remarks Stefano del Giacco, Italy / Ibon Eguiluz-Gracia, Spain / Antonio Spanevello, Italy
As of 17:10	Networking Opportunity
	Join us to our virtual networking community where you can connect and socialize